Lupin's Brazilian subsidiary, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease from Bausch Health.

This move reinforces its commitment to making healthcare solutions accessible to all patients.

“The acquired brands are well established and recognized among doctors and other members of the medical fraternity in Brazil for their reliability, safety, and trustworthiness,” said Alexandre Franca, Managing Director, MedQuímica.

“This transaction enhances our product portfolio in Brazil and strengthens our position in the prescription market,” added Franca.

MedQuimica Pharmaceutical Industries, with its factory located in the Industrial District of Juiz de Fora, has been operating for 47 years. In 2015, it became part of the Lupin Group, a global pharmaceutical company, and the fifth largest generics company in the United States by prescriptions and eighth largest company for generic medicine in the world. In Brazil, Medquimica develops an extensive line of both solid and liquid medicines classified into five lines: OTC (Over the counter medicines), Branded Generics, Hospital, Generics and Food Supplements.